US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises

US states are restricting or eliminating Medicaid coverage for GLP-1 weight-loss drugs like Ozempic and Wegovy due to rising demand and costs. Experts warn that short-term financial savings may lead to higher long-term health costs from obesity.